Emergence of Fosfomycin Resistance Among ESBL‐Producing Escherichia coli in Abadan, Southwestern Iran Authors: Nabi Jomehzadeh, Ali Fakari Published: 2026 ABSTRACT ABSTRACTBackground and Aim Escherichia coli is a key pathogen responsible for various infections, such as urinary tract infections, gastroenteritis, and wound infections. The increasing occurrence of antimicrobial resistance, particularly in extended‐spectrum β‐lactamase (ESBL)‐producing strains, poses a significant global health threat. This study aimed to assess the prevalence of fosfomycin resistance genes in ESBL‐producing E. coli isolates from Abadan, southwest Iran.MethodsFrom December 2020 to June 2021, 90 E. coli isolates were obtained from clinical labs and healthcare centers affiliated with Abadan University of Medical Sciences. Antimicrobial susceptibility and ESBL production were determined using the disk diffusion method, while polymerase chain reaction was employed to detect relevant resistance genes.ResultsFosfomycin resistance was observed in 5.6% of E. coli isolates. ESBL production occurred in 31.1% of isolates, with over half (53.6%) carrying the bla CTX‐M gene. Among ESBL producers, the glpT gene was the most prevalent (50%), followed by fosA3 (10.7%) and fosC2 (3.6%). Notably, the fosA gene was absent in all examined isolates.ConclusionThis study reveals a rising prevalence of fosfomycin resistance among ESBL‐producing E. coli isolates in Abadan, Iran. Ongoing surveillance of fosfomycin resistance is crucial for informing effective antimicrobial stewardship and treatment strategies. Abbreviations clavulanic acid ceftazidime cefotaxime extended‐spectrum β‐lactamase multidrug‐resistant Introduction Escherichia coli is a pioneer opportunistic pathogen that can lead to various human infections. It is a common cause of urinary tract infections and is also frequently associated with hospital‐acquired infections such as sepsis, wound infections, gastroenteritis, and neonatal meningitis [1]. The global increase in antimicrobial resistance among E. coli strains, observed in both developing and developed nations, represents a substantial public health challenge due to the rapidly escalating resistance rates [2]. Notably, the incidence of extended‐spectrum β‐lactamase (ESBL)‐producing Enterobacteriaceae, including E. coli, has experienced a marked rise, thereby restricting treatment options for infections caused by these multidrug‐resistant (MDR) strains [3, 4]. Fosfomycin, as an alternative antibiotic for the treatment of MDR Gram‐negative bacilli, including carbapenem‐resistant E. coli, continues to demonstrate efficacy with low global resistance rates (1%–3%) and minimal cross‐resistance with other classes of antimicrobial agents [5, 6]. However, the emergence of fosfomycin resistance can occur through mechanisms such as reduced membrane permeability, mutations in chromosomal genes such as glpT, or the synthesis of fosfomycin‐inactivating enzymes, such as FosA‐type metalloenzymes, which conjugate glutathione to the antibiotic [5, 7, 8]. Additionally, the presence of conjugative plasmids harboring fosA3 and fosC2 genes, often co‐existing with CTX‐M‐type ESBL genes, contributes to concurrent resistance to both fosfomycin and broad‐spectrum cephalosporins [6, 9]. Despite fosfomycin's established role in managing UTIs and other bacterial infections, the emergence of resistance poses a threat to its therapeutic efficacy [10]. This study investigated the prevalence of fosfomycin resistance and characterized the associated chromosomal and plasmid‐mediated resistance genes in clinical isolates of ESBL‐producing E. coli from Abadan, southwestern Iran. The primary objective was to elucidate the molecular mechanisms underlying fosfomycin resistance and to assess the distribution of key resistance determinants within the local population of ESBL‐producing E. coli. Methods Bacterial Isolates Ninety non‐duplicate E. coli strains were isolated from urine, blood, sputum, and pus specimens using sheep blood agar and MacConkey agar (Liofilchem, Italy). Identification was confirmed through standard bacteriological and biochemical assays, including the TSI test, motility assessment, indole production, urease activity, lysine decarboxylase test, MR‐VP test, and Simmons' citrate test. Susceptibility Testing Antimicrobial susceptibility was assessed using the disk diffusion method as per Clinical and Laboratory Standards Institute (CLSI) guidelines [11]. The antimicrobial agents tested included fosfomycin, ciprofloxacin, tobramycin, amikacin, gentamicin, nitrofurantoin, trimethoprim‐sulfamethoxazole, tetracycline, and amoxicillin/clavulanic acid (CA) (Rosco, Denmark). E. coli ATCC 25922 served as the quality control strain. Isolates resistant to three or more classes of antimicrobials were categorized as MDR. Evaluation of ESBL Production ESBL production was evaluated using the double‐disk synergy test following the 2023 CLSI guidelines [11]. Discs of cefotaxime (CTX) (30 μg) and ceftazidime (CAZ) (30 μg), both alone and combined with CA (10 μg) (Rosco, Denmark), were utilized. Klebsiella pneumoniae ATCC 700603 served as the positive control. Polymerase Chain Reaction (PCR) Amplification of Resistance Genes The genomic DNA required for PCR was extracted via the boiling method described previously [12]. The detection of fos genes and the bla CTX‐M gene in fosfomycin‐resistant isolates was conducted through conventional PCR employing the primers and conditions listed in Table 1 [13, 14, 15]. The PCRs were carried out with a final volume of 25 μL containing 12.5 μL of PCR master mix (SinaClon Co., Iran), 2 μL of template DNA (100 ng/μL),1 μL of each primer (10 pmol/μL), and 8.5 μL nuclease‐free water. The PCR conditions were 5 min at 95°C, followed by 30 cycles of 30 s at 95°C, 30 s at 52°C, and 30 s at 72°C, with a final elongation of 5 min at 72°C. Table 1Primers used to identify resistance genes.Target genePrimer sequencesProduct size (bp)Annealing temp (°C)References fosA F: ATCTGTGGGTCTGCCTGTCGT R: ATGCCCGCATAGGGCTTCT 27150[13] fosA3 F: CCTGGCATTTTATCAGCAGT R: CGGTTATCTTTCCATACCTCAG 22155[13] fosC2 F: TGGAGGCTACTTGGATTTG R: AGGCTACCGCTATGGATTT 20950[13] bla CTX‐M F: ACCGCCGATAATTCGCAGAT R: GATATCGTTGGTGGTGCCATAA 58558[14] glpT F: GCGAGTCGCGAGTTTTCATTG R: GGCAAATATCCACTGGCACC 135963[15]John Wiley & Sons, Ltd. Primers used to identify resistance genes. F: ATCTGTGGGTCTGCCTGTCGT R: ATGCCCGCATAGGGCTTCT F: CCTGGCATTTTATCAGCAGT R: CGGTTATCTTTCCATACCTCAG F: TGGAGGCTACTTGGATTTG R: AGGCTACCGCTATGGATTT F: ACCGCCGATAATTCGCAGAT R: GATATCGTTGGTGGTGCCATAA F: GCGAGTCGCGAGTTTTCATTG R: GGCAAATATCCACTGGCACC Results Microbiological and biochemical assays identified 90 non‐duplicate E. coli isolates from clinical specimens, primarily from urine (82.2%), followed by blood (7.8%), sputum (5.6%), and pus (4.4%). The Kirby–Bauer method highlighted significant antimicrobial resistance, with tobramycin showing the highest resistance at 84.4%, followed by cefazolin (77.8%) and cefamandole (64.4%). In contrast, CAZ/avibactam and fosfomycin were notably effective, with susceptibility rates of 100% and 94.4%, respectively (Table 2). Table 2Antimicrobial resistance pattern of Escherichia coli isolates.AntimicrobialsSensitive, n (%)Intermediate, n (%)Resistant, n (%)Fosfomycin85 (94.4)0.05 (5.6)Doxycycline37 (41.1)6 (6.7)47 (52.2)Cefazolin19 (21.1)1 (1.1)70 (77.8)Cefamandole26 (28.9)6 (6.7)58 (64.4)Tobramycin14 (15.5)0.076 (84.4)Norfloxacin76 (84.4)2 (2.2)12 (13.3)Mecillinam79 (87.8)5 (5.5)6 (6.7)Tigecycline84 (93.3)0.06 (6.7)Ceftazidime/avibactam100 (100)0.00.0John Wiley & Sons, Ltd. Antimicrobial resistance pattern of Escherichia coli isolates. Phenotypic testing revealed that 31.1% of isolates were ESBL producers. PCR testing for the bla CTX‐M gene showed that 15 of these ESBL‐positive strains (53.6%) carried the gene, while 12 ESBL‐negative strains (19.4%) also tested positive. The glpT gene was the most prevalent among fosfomycin resistance genes, occurring at a rate of 18.9%, with fosA3 and fosC2 at lower rates of 4.4% and 1.1%, respectively. Notably, none of the isolates contained the fosA gene. Half (50%) of the ESBL‐producing strains had the glpT gene, with 10.7% and 3.6% also testing positive for fosA3 and fosC2, respectively (Figure 1). Out of the five fosfomycin‐resistant isolates, four contained the glpT gene, three had the fosA3 gene, and a single isolate possessed the fosC2 gene. Distribution of antibiotic resistance genes. Discussion This study examined the prevalence and genetic factors of ESBL production and fosfomycin resistance in clinical isolates, highlighting an alarming overlap in resistance mechanisms. Despite the availability of fosfomycin for over three decades [15], its limited prescription in the region has likely contributed to the observed low resistance rates among clinical E. coli isolates. These findings underscore the need for ongoing surveillance to maintain the efficacy of fosfomycin, particularly in the treatment of infections that are resistant to other antibiotics. Antimicrobial susceptibility testing in the present study demonstrated that only a small percentage of the isolates (5.6%) were resistant to fosfomycin, a finding that aligns with prior reports by Ghotaslou et al. [1], Fozouni [16], and Li et al. [15]. Similarly, a systematic review and meta‐analysis by Falagas et al. indicated that 96.8% of ESBL‐producing E. coli isolates remained susceptible to fosfomycin [17]. In contrast, a multicenter study by Galindo‐Mendez et al. [9], involving patients from 18 diagnostic and treatment centers across 13 Mexican cities, reported a 10.9% fosfomycin resistance rate among urinary E. coli isolates. This rate surpasses those observed in our investigation as well as in comparable studies conducted in France [13], Switzerland [18], the United States [19], and Sweden [20]. The disparities and congruences between our findings and those of similar studies may arise from the limited prescribing practices and accessibility of fosfomycin in Iranian healthcare. Such careful use can reduce selective pressure and delay the development of resistance in bacterial populations. Although fosfomycin shows significant promise in treating Gram‐negative bacterial infections, due to its unique mechanism that bypasses common resistance pathways, emerging resistance reports highlight ongoing challenges, necessitating vigilant monitoring to prevent widespread resistance. Phenotypic testing revealed that 31.1% of isolates were ESBL producers, consistent with recent hospital‐based studies reporting elevated prevalence rates of ESBLs in clinical E. coli isolates both in Iran and globally [21, 22]. The consistently high frequency of ESBL‐producing strains reflects ongoing selection pressure due to the extensive use of beta‐lactam antibiotics and highlights the challenges associated with managing plasmid‐mediated resistance in hospital settings [23]. However, some studies have reported lower prevalence rates of ESBL‐producing E. coli, such as an overall pooled prevalence of 20.76% across sub‐Saharan Africa [24] and 12.6% in Jordan [25]. These differences may be attributed to geographic variations, sample types, and study methodologies. Over half (53.6%) of ESBL‐positive isolates exhibited the bla CTX‐M gene, underscoring its status as the dominant ESBL determinant worldwide [26]. This prevalence is associated with the widespread dissemination of CTX‐M‐type enzymes through plasmid transfer and clonal expansion [22, 27]. Interestingly, 19.4% of phenotypically ESBL‐negative isolates also carried bla CTX‐M, indicating potential subclinical carriage or suppressed gene expression. The observed discrepancies between phenotype and genotype may stem from variations in promoter strength, gene copy number, or the presence of non‐functional alleles [28, 29]. This situation highlights the necessity of integrating both phenotypic and molecular approaches in hospital surveillance to ensure accurate identification of resistant strains. Fosfomycin resistance in E. coli has increasingly shifted from being primarily attributed to chromosomal mutations affecting antibiotic uptake to plasmid‐mediated mechanisms that facilitate horizontal gene transfer [30, 31]. This study focused on the glpT gene linked to transport deficiencies and plasmid‐mediated fos genes in ESBL‐producing E. coli. The glpT gene was detected in 18.9% of cases, followed by fosA3 at 4.4% and fosC2 at 1.1%, while fosA was absent. The predominance of glpT‐related resistance underscores its significance in the glycerol‐3‐phosphate transporter pathway [20]. Inactivation of glpT has emerged as a major contributor to low‐to‐moderate resistance in Enterobacterales, particularly among isolates subjected to extended fosfomycin therapy [7]. The absence of fosA may indicate a limited circulation of fosA‐bearing plasmids within the studied population, as these genes are more commonly associated with K. pneumoniae and Enterobacter cloacae complex [7, 32]. The significant prevalence of the glpT gene, identified in 18.9% of isolates overall and in 50% of ESBL‐positive isolates, is a notable finding of this study. However, it is essential to recognize that the presence of a resistance gene does not necessarily imply the expression of a resistant phenotype [33, 34]. Various factors, including gene expression levels, regulatory mutations, and metabolic context, can influence whether a gene confers detectable resistance. Although glpT was detected in 17 isolates, only 5 exhibited phenotypic resistance to fosfomycin. This suggests that some glpT‐positive isolates may harbor non‐functional or silent variants of the gene, or that compensatory mechanisms, such as upregulation of the uhpT transporter, may offset the impact of glpT disruption [35, 36]. Prior studies have reported discrepancies between genotypic detection and phenotypic resistance, underscoring the importance of integrating molecular detection results with phenotypic data to inform clinical decision‐making [18, 36]. The simultaneous presence of ESBL and fosfomycin resistance poses a significant challenge to hospital infection control. The dissemination of plasmid‐encoded genes that confer MDR not only restricts therapeutic options but also complicates empirical treatment strategies. Therefore, routine screening for fosfomycin resistance, together with ESBL surveillance, is recommended in settings where fosfomycin is reintroduced as part of antimicrobial stewardship programs [7, 17]. Additionally, genomic analyses could elucidate the genetic contexts of these resistance determinants, including plasmid types, integron structures, and associated mobile elements, thereby informing infection prevention strategies and guiding antibiotic policies. To reinforce the therapeutic utility of fosfomycin, we recommend conducting a comprehensive multicenter study across diverse geographic regions. While this study yields valuable findings, several limitations warrant acknowledgment, including the relatively modest sample size, incomplete assessment of all fos genes, absence of plasmid profiling, and the lack of sequencing for the glpT and bla CTX‐M PCR amplicons. Conclusions This investigation demonstrates that clinical isolates of E. coli from the examined region primarily exhibit susceptibility to fosfomycin. However, the rising risk of increasing resistance poses a substantial concern. These findings underscore the necessity for ongoing and rigorous surveillance of antimicrobial susceptibility patterns, particularly in relation to fosfomycin, given its essential role in the treatment of infections caused by ESBL‐producing and other resistant bacterial strains. Continued and diligent monitoring is crucial to sustain the clinical effectiveness of fosfomycin and to inform evidence‐based treatment protocols. Author Contributions Nabi Jomehzadeh: supervision, funding acquisition, writing – original draft, writing – review and editing, project administration, conceptualization. Ali Fakari: methodology, data curation, writing – original draft, investigation. The final manuscript was read and approved by all the authors. Ethics Statement The study was ethically approved by the Abadan University of Medical Sciences, Abadan, Iran (ethics number: IR.ABADANUMS.REC.1399.180). In addition, AI‐assisted technologies, such as Quillbot (https://quillbot.com/) and Grammarly (https://www.grammarly.com/), were employed to enhance the readability and language quality of certain sections of this work. The application of these technologies was conducted with human oversight and control, ensuring that all content underwent thorough review and meticulous editing. Following the utilization of these services, the authors assume full responsibility for the publication's content. Consent Verbal or informed consent was not required because the study focused on microorganisms isolated from clinical specimens without patient contact. However, the formal ethics form was also submitted for the manuscript. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement The corresponding author (Dr. Nabi Jomehzadeh) affirms that this manuscript, entitled “Emergence of Fosfomycin Resistance among ESBL‐Producing Escherichia coli in Abadan, Southwestern Iran,” is an honest, accurate, and transparent account of the study reported. No important aspects of the study have been omitted, and any discrepancies from the planned (and, if relevant, registered) study have been fully explained.